In the subsequent dose levels with continuous administration of dacomitinib, DLTs were reported in two out of 21 patients: grade 3 AST/ALT increase (dose-level 2) and grade 3 skin rash (dose-level 5), respectively (Fig. 1). The gene discussed is GPT; the disease is exanthem.